Inhibrx Biosciences, Inc.

Inhibrx is heading to #ASCO26, where updated data in #chondrosarcoma and #ColorectalCancer from the ozekibart (#INBRX109) program will be presented. Visit our medical booth (#37116) to connect with our team and learn more about our ongoing research.

Inhibrx is excited to share a clinical update on #INBRX106 in first-line head and neck cancer. Read the full press release on our website here: inhibrxbiosciences.investorroom.com/2026-05-11-Inh… #Biotech #INHIBRX #HNSCC

#NationalCancerResearchMonth is a reminder that progress in oncology depends on continued scientific discovery. Research remains essential to improving our understanding of cancer and advancing new approaches. Learn more about our oncology research: tinyurl.com/3fvc74af

Progress in childhood cancers depends on continued research, collaboration, and determination—and we are proud to be part of that effort with our ozekibart program in #EwingSarcoma. Learn more: tinyurl.com/4vt9bnpu #SarcomaResearch #INBRX109 #Biotech

We remain committed to pursuing science that may help address significant unmet needs and contribute to the future of treatment innovation.

Students had the opportunity to explore a professional biotech environment as part of a design-thinking challenge tied to their labs. We are proud to support future pathways in science.

Inhibrx was pleased to partner with the Linda Vista Innovation Center by welcoming military-connected students from the Chula Vista Elementary School District to our office for a field trip as part of their biotech camp.

We hosted our first Great Book Exchange while sharing stories and giving pre-loved books a new home. Staff enjoyed getting their artistic juices flowing through painting flowerpots and planting new life to brighten our workspace. #CompanyCulture #EarthDay2026 #TeamBuilidng

𝘛𝘩𝘦 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩 𝘰𝘧 𝘰𝘶𝘳 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘳𝘰𝘰𝘵𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩 𝘰𝘧 𝘰𝘶𝘳 𝘤𝘶𝘭𝘵𝘶𝘳𝘦! This week, we celebrated #EarthDay with a few green initiatives. Taking the time for intentional connection, space to create & recharge as a team.

Inhibrx is excited to share a clinical update on ozekibart (INBRX-109) in late line colorectal cancer. Read the full press release on our website: tinyurl.com/3dncyvf6 #Biotech #INBRX109 #INHIBRX

These presentations reflect our continued commitment to improving patient outcomes. Learn more here: tinyurl.com/4m54p294

➡️ Oral presentation: Secondary efficacy endpoints from the Phase 2 ChonDRAgon study in conventional chondrosarcoma ➡️ Poster presentation: Phase 1 study of ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma

We’re proud to announce that two abstracts from our ozekibart (INBRX-109) program have been accepted for presentation at the upcoming #ASCO26

Our team is attending the AACR Annual Meeting 2026, a gathering of the global cancer community to share the latest advances in oncology research. Connect with our team and learn more about our oncology research: tinyurl.com/vfny4xty #AACR26

Our team is in Colorado for the 2nd Annual Rocky Mountain Sarcoma Symposium, connecting with clinicians and researchers to discuss advances in multidisciplinary sarcoma care. Learn more about our advancing research in sarcoma here: tinyurl.com/ycke3ybs

Inhibrx is proud to support the Swedish Sarcoma Patient Advocacy Association’s Sarcoma Day on April 17, bringing together the sarcoma patient and healthcare communities. Learn more about our research in sarcoma: tinyurl.com/ycke3ybs #Inhibrx #INBRX109 #SwedishSarcomaDay

Learn more about our ongoing research efforts in #chondrosarcoma and #EwingSarcoma with our ozekibart (#INBRX109) program: tinyurl.com/ycke3ybs

Inhibrx is proud to support the @nwsarcoma as a Corporate Partner. Through education programs, patient support initiatives, and community events, the foundation works to ensure that people affected by sarcoma have access to resources, support, and advocacy.

#Sarcoma is a rare group of cancers that develops in connective tissues such as bone and soft tissue. These complex cancers continue to highlight the need for ongoing research to address unmet medical needs. Learn more about our sarcoma research: tinyurl.com/ycke3ybs

April is #HeadAndNeckCancerAwarenessMonth – a time to raise awareness, support patients and caregivers, and highlight the ongoing need for innovation in treatment. Many patients still face significant unmet medical needs. Learn more about our work: tinyurl.com/j2he79ns